Xenetic Biosciences Surges 141% on $630M Volume Spike, Ranks 174th in U.S. Trading Activity

On October 8, 2025, Xenetic Biosciences (XBIO) surged 141.49% to close trading, with a total volume of $630 million, marking a 550,786.9% increase from the previous day's trading volume. The stock ranked 174th in volume among all listed equities, reflecting intense short-term trading activity.

Recent developments indicate heightened market speculation surrounding XBIO's unannounced preclinical data, with limited guidance provided by management on timelines for public disclosure. Analysts note that the absence of regulatory filings or formal partnerships has created a vacuum for speculative trading, though no concrete catalysts have been disclosed to justify the sharp price movement.

To run this back-test rigorously I need to pin down a few practical details: Market universe - Should we screen U.S.-listed common stocks only (NYSE + NASDAQ), or do you want a different universe? Portfolio construction - Equal-weight each of the 500 names every day (i.e., 0.2% per position) and rebalance daily? Any cash drag / un-invested cash allowed if fewer than 500 names trade on a given day? Transaction costs & slippage - Assume zero, fixed commission (e.g., $0.005/share), or a bps-based spread? Data source preference - If you have a specific data provider in mind (e.g., CRSP, Quandl, Polygon), let me know. Once these are clarified I’ll generate the daily buy/sell signals, feed them into the back-testing engine and return the full metrics and charts.